Vascular Biogenics Ltd.

NasdaqCM:VBLT Stock Report

Market Cap: US$12.1m

Vascular Biogenics Management

Management criteria checks 4/4

Vascular Biogenics' CEO is Dror Harats, appointed in Jan 2001, has a tenure of 22.75 years. total yearly compensation is $887.62K, comprised of 40.3% salary and 59.7% bonuses, including company stock and options. directly owns 1.47% of the company’s shares, worth $177.68K. The average tenure of the management team and the board of directors is 17.8 years and 5.4 years respectively.

Key information

Dror Harats

Chief executive officer

US$887.6k

Total compensation

CEO salary percentage40.3%
CEO tenure22.8yrs
CEO ownership1.5%
Management average tenure17.8yrs
Board average tenure5.4yrs

Recent management updates

How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

Mar 17
How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

Recent updates

VBL Therapeutics receives non-compliance letter from Nasdaq

Sep 01

VBL Therapeutics GAAP EPS of -$0.12

Aug 15

VBL Therapeutics' late-stage trial for ovarian cancer treatment does not meet main goals

Jul 19

Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

May 18
Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

Vascular Biogenics Trial Nears Full Enrollment, Price Could Jump

Sep 03

How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

Mar 17
How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?

Jan 28
How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?

VBL Therapeutics expands the ovarian cancer trial in Europe

Dec 29

Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

Dec 24
Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 19
Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates

VBL Therapeutics EPS beats by $0.01, misses on revenue

Nov 16

CEO Compensation Analysis

How has Dror Harats's remuneration changed compared to Vascular Biogenics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-US$16m

Mar 31 2023n/an/a

-US$25m

Dec 31 2022US$888kUS$357k

-US$32m

Sep 30 2022n/an/a

-US$38m

Jun 30 2022n/an/a

-US$35m

Mar 31 2022n/an/a

-US$34m

Dec 31 2021US$1mUS$349k

-US$30m

Sep 30 2021n/an/a

-US$28m

Jun 30 2021n/an/a

-US$27m

Mar 31 2021n/an/a

-US$25m

Dec 31 2020n/an/a

-US$24m

Sep 30 2020n/an/a

-US$23m

Jun 30 2020n/an/a

-US$22m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$889kUS$405k

-US$19m

Sep 30 2019n/an/a

-US$18m

Jun 30 2019n/an/a

-US$18m

Mar 31 2019n/an/a

-US$17m

Dec 31 2018US$815kUS$375k

-US$20m

Sep 30 2018n/an/a

-US$10m

Jun 30 2018n/an/a

-US$11m

Mar 31 2018n/an/a

-US$12m

Dec 31 2017n/an/a

-US$10m

Sep 30 2017n/an/a

-US$21m

Jun 30 2017n/an/a

-US$18m

Mar 31 2017n/an/a

-US$16m

Dec 31 2016US$515kUS$406k

-US$16m

Compensation vs Market: Dror's total compensation ($USD887.62K) is about average for companies of similar size in the US market ($USD738.70K).

Compensation vs Earnings: Dror's compensation has been consistent with company performance over the past year.

CEO

Dror Harats (66 yo)

22.8yrs

Tenure

US$887,624

Compensation

Prof. Dror Harats, MD, has been the Chief Executive Officer of Vascular Biogenics Ltd., since January 2001. Prof. Harats founded VBL in 2000 based on many years of research in Atherosclerosis, Vascular Bio...

Leadership Team

NamePositionTenureCompensationOwnership
Dror Harats
CEO & Director22.8yrsUS$887.62k1.47%
$ 177.7k
Samuel Backenroth
Chief Financial Officer2yrsUS$669.08k0.68%
$ 81.9k
Eyal Breitbart
Senior Vice President of Research & Operations17.8yrsUS$433.79kno data
Ayelet Horn
General Counsel23.8yrsno datano data
Erez Feige
Senior Vice President of Business Operations1.7yrsUS$374.71kno data

17.8yrs

Average Tenure

52yo

Average Age

Experienced Management: VBLT's management team is seasoned and experienced (17.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Dror Harats
CEO & Director22.8yrsUS$887.62k1.47%
$ 177.7k
Ruth Alon
Independent Non-Executive Director13.6yrsUS$94.25k0%
$ 0
David Hastings
Independent Non-Executive Director5.8yrsUS$101.30k0%
$ 0
Ruth Arnon
Scientific Consultant & Member of Scientific Advisory Board2.3yrsno datano data
Marc Kozin
Independent Non-Executive Chairman3yrsUS$205.67k0.050%
$ 6.1k
Shmuel Ben-Zvi
Independent Non-Executive Director5.1yrsUS$96.88k0.077%
$ 9.4k
Patrick Wen
Member of Scientific Advisory Boardno datano datano data
Andrew Brenner
Member of Scientific Advisory Boardno datano datano data
Richard Penson
Member of Scientific Advisory Boardno datano datano data
Timothy Cloughesy
Member of Scientific Advisory Boardno datano datano data
Nicholas Butowski
Member of Scientific Advisory Boardno datano datano data
Kathleen Moore
Member of Scientific Advisory Boardno datano datano data

5.4yrs

Average Tenure

64.5yo

Average Age

Experienced Board: VBLT's board of directors are considered experienced (5.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/17 20:03
End of Day Share Price 2023/10/16 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vascular Biogenics Ltd. is covered by 8 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gbolahan Amusa BenzChardan Capital Markets, LLC
Alethia YoungDeutsche Bank
Etzer DaroutGuggenheim Securities, LLC